Although the Duchenne community has collected a wealth of natural history data, translating those data in clinical trial design has proven challenging. Clinical trials have suffered from higher than anticipated variance, masking potential drug effects. The predominant driver of this variance is phenotypic heterogeneity in disease progression. Founded in response to this challenge, cTAP is a dynamic and collaborative alliance forged between clinical experts, patient advocates, and a rapidly growing group of drug developers in Duchenne, who together access sophisticated analytics and data science to address the most important challenges to trial design, analysis and interpretation.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...